Johann E Gudjonsson, MD, PhD
Manage Your Profile
About
Dr. Johann Gudjonsson, MD, PhD is the Arthur C. Curtis Professor of Molecular Skin Immunology and the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. A graduate of the University of Iceland Medical School, he completed his internship and dermatology residency training at the University of Michigan. Dr. Gudjonsson has served on the faculty of the University of Michigan Department of Dermatology since 2008. He provides general medical dermatology patient care at the University of Michigan Taubman Center, and maintains clinical and research interests in inflammatory and autoimmune disorders involving the skin.
Dr. Gudjonsson leads an NIH-funded research group examining the immunological and genetic drivers of inflammatory skin disease, with projects directed at improving the diagnosis and treatment of disorders, such as atopic dermatitis, cutaneous lupus, hidradenitis suppurativa, lichen planus, psoriasis and psoriatic arthritis.
Dr. Gudjonsson's research has been supported by research awards from the National Institutes of Health (NIH), the American Skin Association, Dermatology Foundation, Doris Duke Foundation, among others. He is director of the U-M Skin Research Center (NIH/NIAMS P30) which provides resources, training and support to new and early career investigators engaged in skin research and fosters interdisciplinary engagement and collaboration.
Dr. Gudjonsson is a foremost expert in dermatological science, who received the 2007 Young Investigator Award from the American Academy of Dermatology, was named the 2018 Rising Star Lecturer for the Society for Investigative Dermatology and was recipient of the American Skin Association Research Achievement Award in Psoriasis in 2021. He serves as an Associate Editor for the Journal of Allergy and Clinical Immunology (JACI), and on the Editorial Board of JCI Insight. Dr. Gudjonsson is a standing member of the NIH Arthritis, Connective Tissue and Skin Study Section.
Qualifications
-
PhDUniversity of Iceland, Faculty of Medicine, Vatnsmýrarvegi 16, Reykjavik, 101, Iceland
1998 - 2003
-
MDUniversity of Iceland, Faculty of Medicine, Vatnsmýrarvegi 16, Reykjavik, 101, Iceland
1992 - 1998
-
BSMenntaskolinn i Reykjavik, Reykjavik, Iceland
1988 - 1992
Center Memberships
-
Center MemberTaubman Institute
-
Center MemberAI and Digital Health Innovation
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Recent Publications
-
Blauvelt A, Jiang R, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Billi AC, Matheson RT, Photowala H, Gudjonsson JE, Ehst BD. Nature Communications, 2026 Dec 1; 17 (1):Journal ArticleA randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
DOI:10.1038/s41467-025-67475-0 PMID: 41381642 -
Jiang R, Kirma J, Fox J, Xing X, Wang J, Sarkar MK, Bogle R, Do T, Coon A, Cole C, Plazyo O, Rew JE, Zhang H, Kahlenberg JM, Billi AC, Bachelez H, Tsoi LC, Harms PW, Shao S, Chen X, Gudjonsson JE. Nature Communications, 2026 Dec 1; 17 (1):Journal ArticleDynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis
DOI:10.1038/s41467-025-67917-9 PMID: 41436466 -
Moon JY, Wolf SJ, Joshi AD, Zhang H, Shadiow J, Bauer TM, Mangum KD, Hughes LD, Audu CO, Melvin WJ, Barrett EC, Rocco S, de Jimenez GS, Estor AL, Nelapudi M, Li Q, Bogle R, Levi B, Davis FM, Obi AT, Moore BB, Tsoi LC, Gudjonsson JE, Gallagher KA. Nature Communications, 2026 Dec 1; 17 (1):Journal ArticleIL-17A is increased in diabetic wounds and impairs keratinocyte function via histone demethylase JMJD3
DOI:10.1038/s41467-025-67456-3 PMID: 41413388 -
Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, Gallo G, Okragly A, Wolf E, Xu C, Moser BA, Rueda MJ, Elmaraghy H, Uluckan O, Gudjonsson JE. J Dermatolog Treat, 2026 Dec; 37 (1): 2636417Journal ArticleLebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.
DOI:10.1080/09546634.2026.2636417 PMID: 41814992 -
Gudjonsson J. 2026 Jun 19;PresentationInflammatory Skin Diseases and Fibrosis
-
Jiang R, Blauvelt A, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Chen L, Zhang H, Xing X, Sarkar MK, Plazyo O, Kahlenberg JM, Billi AC, Matheson RT, Photowala H, Ehst BD, Gudjonsson JE. Immunity, 2026 May 28;Journal ArticleA longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit.
DOI:10.1016/j.immuni.2026.05.002 PMID: 42208526 -
Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA, Barker JN, Weidinger S, Modlin RL, Betz RC, Khanna D, Varga J, Kahlenberg JM, He K, Elder JT, Zhou X, Gudjonsson JE, Tsoi LC. J Allergy Clin Immunol, 2026 May 26;Journal ArticleMulti-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes.
DOI:10.1016/j.jaci.2026.05.013 PMID: 42203178 -
Gudjonsson JE, Bier K, Gaulis S, Tsoi LC, Cardner M, Sarkar MK, Coon A, Cole C, Kärner J, Fernandez A, Peters T, Eidsmo L, Iversen L, Jagiello P, Ferrero E, Kolbinger F, Lohmann F, Conrad C. J Allergy Clin Immunol, 2026 May 25;Journal ArticleEarly intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis - STEPIn Mechanistic Sub-study results.
DOI:10.1016/j.jaci.2026.04.028 PMID: 42191094
Featured News & Stories
Researchers identify a potential “Achilles heel” of psoriasis